美股A股
StockGist
Back
10-Q2026-02-12· grok-4-1-fast-non-reasoning

RZLT · Rezolute, Inc.

0001104659-26-014334

SEC filing

Summary

Rezolute, Inc. (RZLT), a clinical-stage biopharmaceutical company, reported a net loss of $22.8 million for the quarter ended December 31, 2025, driven by total operating expenses of $24.2 million, including $14.3 million in research and development and $9.9 million in general and administrative costs. This compares to an operating loss of $24.2 million, partially offset by $1.4 million in interest and other income, net. No revenue was reported, consistent with the company's pre-commercial stage. Comprehensive loss was also $22.8 million after a minor $2K unrealized loss on marketable debt securities. Balance sheet remains strong with total assets of $138.6 million, including $11.9 million in cash and cash equivalents and $121.0 million in marketable debt securities, supporting a robust liquidity position with total current assets of $135.1 million against $9.5 million in current liabilities. Shareholders' equity stood at $128.0 million. Cash flow analysis for the period showed net cash used in operating activities of $29.7 million, investing activities outflow of $45.7 million primarily from net purchases of marketable securities, and financing inflow of $1.3 million, resulting in a net decrease in cash of $82.2 million, with ending cash of $94.1 million. The cash burn reflects ongoing R&D investments, providing runway for clinical programs without immediate revenue generation.

Key takeaways

Full analysis

Performance Summary

Rezolute, Inc. reported a net loss of $22.8 million for the three months ended December 31, 2025, compared to comprehensive loss of the same amount after a $2K net unrealized loss on marketable debt securities. Operating expenses totaled $24.2 million, comprising $14.3 million in research and development and $9.9 million in general and administrative expenses, resulting in an operating loss of $24.2 million. This was offset by $1.4 million in non-operating income, net, including interest income and a $6K gain from change in fair value of embedded derivative liability. Basic and diluted net loss per common share was -$0, based on weighted average shares outstanding of 103.7 million. No prior period figures are provided in the filing for direct QoQ comparison, but cash position supports ongoing operations. Total assets reached $138.6 million, with strong liquidity from current assets of $135.1 million.

Revenue Analysis

No revenue was reported in the period, consistent with Rezolute's clinical-stage biopharmaceutical focus. The company generated no product sales or licensing revenue. Operating expenses reflect investment in R&D programs, with $14.3 million allocated to clinical development and related activities. No segment breakdowns or geographic revenue mix disclosed.

Margins & Profitability

As a pre-revenue biotech, Rezolute reported no gross profit or margins. Operating loss of $24.2 million represented 100% of expenses against zero revenue. Key cost drivers included R&D at $14.3 million (59% of op ex) and G&A at $9.9 million (41%). Non-operating income of $1.4 million improved net results slightly. Share-based compensation contributed $5.9 million to expenses per cash flow reconciliation, indicating non-cash impact on profitability.

Cash Flow & Balance Sheet

Net cash used in operating activities was $29.7 million, adjusted from $40.9M net loss by $5.9M share-based compensation, $1.5M accretion on securities, and working capital changes including -$2.0M decrease in accounts payable. Investing activities used $45.7 million net, from $98.7M purchases offset by $60.7M maturities of marketable debt securities. Financing provided $1.3 million from stock option exercises. Net cash decrease was $82.2 million, with ending cash and equivalents at $94.1 million (note: balance sheet shows $11.9M, likely distinction in classification). Balance sheet shows $135.1M current assets vs. $9.5M current liabilities; total liabilities $10.6M; equity $128.0M with accumulated deficit -$444.8M.

Outlook

No specific management guidance, strategic priorities, or risk factors from forward-looking statements are explicitly disclosed in the provided filing excerpt. Commitments noted in Notes 5, 9, and 10. Cash position of $11.9M plus $121.0M marketable securities provides liquidity for ongoing R&D.